RT期刊文章SR电子T1偏头痛的临床试验有多透明?摩根富首页林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP 1372 1381 10.1212 / WNL OP。83签证官0000000000000866 15 A1 Faustine l·杜夫卡A1罗伯特·h·德沃金A1 Michael c . Rowbotham年2014 UL //www.ez-admanager.com/conten首页t/83/15/1372.abstract AB研究需要公共访问的信息的透明度试验起始和公开可用的结果在研究之前完成。注册偏头痛试验的存储库是一个全球性的快照注册偏头痛临床试验和记分卡通过同行评议的文献结果的可用性,注册表数据库和灰色文献。295独特的临床试验确定雇用了447名临床实验的代理商,154年有30%的急性偏头痛试验和11%的141年偏头痛预防试验测试代理的组合。最常见的研究类别在急性偏头痛试验药物,非甾体类抗炎药、止吐药,降钙素相关基因肽拮抗剂,和对乙酰氨基酚。经常偏头痛预防试验研究抗惊厥药物、β-blockers补充或替代疗法,抗抑郁药,肉毒杆菌毒素。总的来说,237试验合格的搜索结果。163年试验完成至少12个月的早些时候,有57%的同行评议的文献结果,和注册中心/灰色文献又增加了13%。使用逻辑回归分析,研究样本容量低于中位数141受试者明显不太可能有结果,但结果的主导因素与可用性相关研究以来完成。 In unadjusted models, trials registered on ClinicalTrials.gov and trials with industry primary sponsorship were significantly more likely to have results. Recently completed trials rarely have publicly available results; 2 years after completion, the peer-reviewed literature contains results for fewer than 60% of completed migraine trials. To avoid bias, evidence-based therapy algorithms should consider factors affecting results availability. As negative trials are less likely to be published, special caution should be exercised before recommending a therapy with a high proportion of missing trial results.ACTTION=Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; CI=confidence interval; CTG=ClinicalTrials.gov; FDA=Food and Drug Administration; FDAAA=Food and Drug Administration Amendments Act of 2007; ICMJE=International Committee of Medical Journal Editors; ICTRP=International Clinical Trials Registry Platform; NSAID=nonsteroidal anti-inflammatory drugs; OR=odds ratio; RReACT=Repository of Registered Analgesic Clinical Trials; RReMiT=Repository of Registered Migraine Trials

map